– Featured Research Session oral presentation highlights findings that show Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's Disease – – Study meets its key objectives to advance data supporting favorable benefit/risk profile, support target engagement, and provide additional support for the efficacy profile of Lomecel-B™ – – Therapeutic potential demonstrated in MRI biomarker results showing 49% reduction in brain volume loss and improvement in ...

MIAMI, July 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced that its positive Phase 2a clinical trial data and biomarker results were featured in two presentations, including a Featured Research Session oral presentation, at the Alzheimer's Association International Conference® (AAIC), taking place July 28 – August 1, 2024, in Philadelph ...

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The offer and sale of the unregistered warrants in the concurrent private placement were made in a transaction not involving a public offering and have not been registered under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Rule 506(b) of Regulation D promulgated thereunder and, along with the shares of Class A common stock underlying such unregistered warrants, have not been registered ...

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The shares of Class A common stock (or common stock equivalents) offered in the registered direct offering (but excluding the unregistered warrants offered in the concurrent private placement and the shares of Class A common stock underlying such unregistered warrants) were offered and sold by the Company pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-264142), including a base prospectus, previousl ...

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common ...

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Class A common ...

This has the Food and Drug Administration (FDA) granting this designation to Lomecel-B. This will help assist with the speedy development and review of the treatment. That allows for the drug to make it to market sooner than it would without fast-track status. With this fast-track designation news comes heavy trading of LGVN stock on Wednesday. That has more than 23 million shares on the move as of this writing. This is well above its daily average trading volume of about 9.6 million shares. On Penny Stocks ...

Longeveron (NASDAQ:LGVN) stock is rocketing higher on Wednesday after the clinical-stage biotechnology company announced a new designation from the Food and Drug Administration (FDA). The FDA has granted Longeveron's Lomecel-B the Regenerative Medicine Advanced Therapy (RMAT) designation. This is the company's treatment for mild Alzheimer's Disease. This is big news for LGVN stockholders as it marks the first time the RMAT designation has been granted to a cellular therapeutic Alzheimer's treatment candidat ...

MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B™ for the treatment of mild Alzheimer's Disease. Lomecel-B™ is a proprietary, scalable, allogeneic cellular investigational therapy being ...

Longeveron previously announced top-line results for the CLEAR MIND Phase 2a clinical trial on October 5, 2023, and reported additional clinical data and imaging biomarker results on December 20, 2023. Full study results for CLEAR MIND will be reported in a Featured Research Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC) on July 28, 2024. The RMAT designation is the fourth special regulatory designation received by Longeveron for Lomecel-B™. The Lomecel-B™ HLHS program ...